TG-100435

• Description :

  TG-100435 is a multitargeted, orally active protein tyrosine kinase inhibitor, with Ki of 13 to 64 nM for Src, Lyn, Abl, Yes, Lck, and EphB4. TG-100435 plays an important role in cancer research[1].

• UNSPSC :

  12352005

• Target :

  Bcr-Abl; Ephrin Receptor; Src

• Related Pathways :

  Protein Tyrosine Kinase/RTK

• Field of Research :

  Cancer

• Smiles :

  ClC1=C(C2=CC3=C(C(C)=C2)N=C(NC4=CC=C(C=C4)OCCN5CCCC5)N=N3)C(Cl)=CC=C1

• Molecular Formula :

  C26H25Cl2N5O

• Molecular Weight :

  494.42

• References & Citations :

  [1]Steven X Hu, et al. Metabolism and pharmacokinetics of a novel Src kinase inhibitor TG100435 ([7- (2,6-dichloro-phenyl) -5-methyl-benzo[1,2,4]triazin-3-yl]-[4- (2-pyrrolidin-1-yl-ethoxy) -phenyl]-amine) and its active N-oxide metabolite TG100855 ([7- (2,6-dichloro-phenyl) -5-methylbenzo[1,2,4]triazin-3-yl]-{4-[2- (1-oxy-pyrrolidin-1-yl) -ethoxy]-phenyl}-amine) . Comparative Study Drug Metab Dispos. 2007 Jun;35 (6) :929-36.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [867330-68-5]